Currently there is insufficient knowledge of how material properties at the nanoscale level could induce chronic toxicological injury. Addressing this knowledge gap is important for the safety assessment of engineered nanomaterials (ENMs) and the implementation of risk reduction strategies. Our long-term goal is to develop a fundamental understanding of the mechanisms by which industrially important ENMs mediate lung injury and use of this information to formulate predictive toxicological approaches that can be used for ENM safety assessment and safer design. The overall objective of this competitive renewal application is to develop a predictive paradigm for chronic pulmonary toxicity that is premised on the unique properties of rare earth oxide (REO) and fumed silica NPs towards engaging the NLRP3 inflammasome and disrupting the autophagy quality control mechanisms that regulate these inflammasomes. Our central hypothesis is that the (i) biocatalytic transformation of REOs into highly reactive REO-PO4 nanocrystals in the lysosome, and (ii) hydration- dependent reconstruction and display of highly reactive silanols on fumed silica NPs are responsible for sustained NRLP3 activation and autophagy blockade, leading to macrophage activation, epithelial- mesenchymal transition (EMT), and ultimately delayed or chronic pulmonary inflammation and fibrosis. The rationale for the proposed research is that, once it is known how unique nanoscale properties of the fumed silica and oxide NPs induce chronic lung injury, we can use this predictive paradigm for expedited safety assessment as well as safer design of these materials. Guided by strong preliminary data, this hypothesis will be tested by pursuing three specific aims:
Aim 1 : To develop a predictive toxicological paradigm for chronic lung injury that is premised on rare earth oxide NP properties leading to lysosomal injury, NLRP3 inflammasome assembly and autophagy dysfunction. This scenario will be compared against acute lung injury by transition metal oxides.
Aim 2 : To develop a predictive toxicological paradigm that relates the framework chemistry and hydration status of fumed silica nanoparticles to a lysosome-independent mechanism of NLRP3 inflammasome activation, which originates at the surface membrane.
Aim 3 : To demonstrate that systematic control of the precursor chemistry and hydration conditions during flame spray pyrolysis (FSP) can be used to produce safer fumed silica NPs. Our approach is innovative, because we use a predictive toxicological paradigm that is premised on structure-activity relationships (SARS) linking cellular injury response pathways to the pathophysiology of chronic lung injury. The proposed research is significant because: (i) we will introduce a robust, quantitative scientific platform to assess ENM safety; (ii) ability to predict in vivo toxicological scenarios that reduce the need for expensive chronic exposure studies in animals; (iii) ability to speed up the rate of safety assessment and regulatory decision-making, commensurate with the number of new applications based on above material categories; (iv) development of SARs for the safer design of fumed silica NPs.

Public Health Relevance

The proposed research is relevant to public health because we seek to establish a robust scientific platform for safety assessment of commercially important engineered nanomaterials to which workers and consumers are increasingly being exposed. The proposed research is relevant to the NIEHS's mission that pertains to reducing the burden of human illness and disability by understanding how the products from an emerging new technology may generate human disease, including how to evaluate those materials for safer design.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES016746-08
Application #
8829854
Study Section
Nanotechnology Study Section (NANO)
Program Officer
Balshaw, David M
Project Start
2008-05-15
Project End
2018-02-28
Budget Start
2015-03-01
Budget End
2016-02-29
Support Year
8
Fiscal Year
2015
Total Cost
$346,500
Indirect Cost
$121,500
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Manshian, Bella B; Poelmans, Jennifer; Saini, Shweta et al. (2018) Nanoparticle-induced inflammation can increase tumor malignancy. Acta Biomater 68:99-112
Hwang, Ruth; Mirshafiee, Vahid; Zhu, Yifang et al. (2018) Current approaches for safer design of engineered nanomaterials. Ecotoxicol Environ Saf 166:294-300
Mirshafiee, Vahid; Sun, Bingbing; Chang, Chong Hyun et al. (2018) Toxicological Profiling of Metal Oxide Nanoparticles in Liver Context Reveals Pyroptosis in Kupffer Cells and Macrophages versus Apoptosis in Hepatocytes. ACS Nano 12:3836-3852
Naatz, Hendrik; Lin, Sijie; Li, Ruibin et al. (2017) Safe-by-Design CuO Nanoparticles via Fe-Doping, Cu-O Bond Length Variation, and Biological Assessment in Cells and Zebrafish Embryos. ACS Nano 11:501-515
Kunz-Schughart, Leoni A; Dubrovska, Anna; Peitzsch, Claudia et al. (2017) Nanoparticles for radiooncology: Mission, vision, challenges. Biomaterials 120:155-184
Jiang, Wen; Wang, Xiang; Osborne, Olivia J et al. (2017) Pro-Inflammatory and Pro-Fibrogenic Effects of Ionic and Particulate Arsenide and Indium-Containing Semiconductor Materials in the Murine Lung. ACS Nano 11:1869-1883
Mirshafiee, Vahid; Jiang, Wen; Sun, Bingbing et al. (2017) Facilitating Translational Nanomedicine via Predictive Safety Assessment. Mol Ther 25:1522-1530
Xia, Tian (2017) Multifunctional nanotherapeutics for treatment of ocular disease. Ann Eye Sci 2:
Cai, Xiaoming; Lee, Anson; Ji, Zhaoxia et al. (2017) Erratum to: Reduction of pulmonary toxicity of metal oxide nanoparticles by phosphonate-based surface passivation. Part Fibre Toxicol 14:33
Wang, Xiang; Sun, Bingbing; Liu, Sijin et al. (2017) Structure Activity Relationships of Engineered Nanomaterials in inducing NLRP3 Inflammasome Activation and Chronic Lung Fibrosis. NanoImpact 6:99-108

Showing the most recent 10 out of 59 publications